Well-Differentiated Gastric Tumors/Carcinomas
Philippe Ruszniewski(Inserm), Guido Rindi(University of Parma), Guillaume Cadiot(Université Claude Bernard Lyon 1), Réza Kianmanesh, Daniel C. Chung(Icahn School of Medicine at Mount Sinai), Beata Kos‐Kudła, Håkan Ahlman(University of Gothenburg), Dik J. Kwekkeboom(Erasmus MC), Rudolf Arnold(Philipps University of Marburg), Gianfranco Delle Fave(Sapienza University of Rome), Stanislas Pauwels, Paul Komminoth(Triemli Hospital)
Cited by 154
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k